# Aurinia Pharmaceuticals Inc. (AUPH) FY2026 Q2 P&L / Income Statement

- Company: Aurinia Pharmaceuticals Inc. (AUPH)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-06, accession number 0001600620-26-000062
- Page: https://plicit.ai/financials/auph/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/auph-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenue**: 83,220,000 US dollars
- **Cost of revenue**: 6,555,000 US dollars
- **Gross profit (calculated)**: 76,665,000 US dollars
- **Operating expenses (calculated)**: 30,324,000 US dollars
- **Income from operations**: 46,341,000 US dollars
- **Other income (expense), net (calculated)**: 2,445,000 US dollars
- **Net income before income taxes**: 48,786,000 US dollars
- **Income tax expense**: 11,372,000 US dollars
- **Net income**: 37,414,000 US dollars
- **Net product sales**: 79,412,000 US dollars
- **License, collaboration and royalty revenue**: 3,808,000 US dollars
- **Research and development**: 13,050,000 US dollars
- **Selling, general and administrative**: 23,508,000 US dollars
- **Other (income) expense, net**: negative 6,234,000 US dollars
- **Restructuring**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.